Literature DB >> 26017392

Prostanoids and NSAIDs in cardiovascular biology and disease.

Babettte B Weksler1.   

Abstract

Prostanoids and related arachidonic acid derivatives are important physiologic modulators in arteries, as well as mediators of inflammation, hemostasis, and cell proliferation. Their participation in atherosclerosis and in acute thrombotic events is complex, as demonstrated by untoward cardiovascular (CV) effects associated with clinical use of inhibitors of prostaglandin synthesis for treatment of chronic pain, inflammatory states, or cancer prophylaxis. Newer understanding of the pathophysiology of atherosclerosis and the pharmacology of prostanoids promises potential resolution of current problems resulting from the hazards of available prostanoid-altering drugs.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26017392     DOI： 10.1007/s11883-015-0514-9

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  55 in total

1.  Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice.

Authors:  Lihong Chen; Guangrui Yang; James Monslow; Leslie Todd; David P Cormode; Jun Tang; Gregory R Grant; Jonathan H DeLong; Soon Yew Tang; John A Lawson; Ellen Pure; Garret A Fitzgerald
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-21       Impact factor: 11.205

2.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

3.  Human pharmacology of naproxen sodium.

Authors:  Marta L Capone; Stefania Tacconelli; Maria G Sciulli; Paola Anzellotti; Luigia Di Francesco; Gabriele Merciaro; Patrizia Di Gregorio; Paola Patrignani
Journal:  J Pharmacol Exp Ther       Date:  2007-05-01       Impact factor: 4.030

4.  Acetylation of prostaglandin synthase by aspirin.

Authors:  G J Roth; N Stanford; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

Review 5.  Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation.

Authors:  V Capra; M Bäck; D J Angiolillo; M Cattaneo; K S Sakariassen
Journal:  J Thromb Haemost       Date:  2014-02       Impact factor: 5.824

6.  Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation.

Authors:  G A FitzGerald; B Smith; A K Pedersen; A R Brash
Journal:  N Engl J Med       Date:  1984-04-26       Impact factor: 91.245

7.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

Authors:  B F McAdam; F Catella-Lawson; I A Mardini; S Kapoor; J A Lawson; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

8.  Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice.

Authors:  Takuya Kobayashi; Yoshio Tahara; Mayumi Matsumoto; Masako Iguchi; Hideto Sano; Toshinori Murayama; Hidenori Arai; Hiroji Oida; Takami Yurugi-Kobayashi; Jun K Yamashita; Hiroyuki Katagiri; Masataka Majima; Masayuki Yokode; Toru Kita; Shuh Narumiya
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

9.  Effect of S-aspirin, a novel hydrogen-sulfide-releasing aspirin (ACS14), on atherosclerosis in apoE-deficient mice.

Authors:  Huili Zhang; Changfa Guo; Alian Zhang; Yuqi Fan; Ting Gu; Duojiao Wu; Anna Sparatore; Changqian Wang
Journal:  Eur J Pharmacol       Date:  2012-10-16       Impact factor: 4.432

10.  Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors.

Authors:  Mariangela Biava; Claudio Battilocchio; Giovanna Poce; Salvatore Alfonso; Sara Consalvi; Angela Di Capua; Vincenzo Calderone; Alma Martelli; Lara Testai; Lidia Sautebin; Antonietta Rossi; Carla Ghelardini; Lorenzo Di Cesare Mannelli; Antonio Giordani; Stefano Persiani; Milena Colovic; Melania Dovizio; Paola Patrignani; Maurizio Anzini
Journal:  Bioorg Med Chem       Date:  2013-12-18       Impact factor: 3.641
View more
  4 in total

1.  Differential Effects of sEH Inhibitors on the Proliferation and Migration of Vascular Smooth Muscle Cells.

Authors:  Hyo Seon Kim; Sang Kyum Kim; Keon Wook Kang
Journal:  Int J Mol Sci       Date:  2017-12-11       Impact factor: 5.923

2.  Fatty acid desaturase 2 is up-regulated by the treatment with statin through geranylgeranyl pyrophosphate-dependent Rho kinase pathway in HepG2 cells.

Authors:  Shou Tanaka; Noriko Ishihara; Sawako Suzuki; Yasuhiro Watanabe; Daiji Nagayama; Takashi Yamaguchi; Masahiro Ohira; Atsuhito Saiki; Tomoaki Tanaka; Ichiro Tatsuno
Journal:  Sci Rep       Date:  2019-07-10       Impact factor: 4.379

3.  Creating a mouse model resistant to induced ischemic stroke and cardiovascular damage.

Authors:  Qing-Lan Ling; Anita J Mohite; Emma Murdoch; Hironari Akasaka; Qun-Ying Li; Shui-Ping So; Ke-He Ruan
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

4.  Atorvastatin increases Fads1, Fads2 and Elovl5 gene expression via the geranylgeranyl pyrophosphate-dependent Rho kinase pathway in 3T3-L1 cells.

Authors:  Noriko Ishihara; Sawako Suzuki; Shou Tanaka; Yasuhiro Watanabe; Daiji Nagayama; Atsuhito Saiki; Tomoaki Tanaka; Ichiro Tatsuno
Journal:  Mol Med Rep       Date:  2017-08-02       Impact factor: 2.952
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.